<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4314">
  <stage>Registered</stage>
  <submitdate>13/11/2013</submitdate>
  <approvaldate>13/11/2013</approvaldate>
  <nctid>NCT02004522</nctid>
  <trial_identification>
    <studytitle>A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)</studytitle>
    <scientifictitle>A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>IPI-145-07</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Lymphocytic Leukemia</healthcondition>
    <healthcondition>Small Lymphocytic Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - IPI-145 (duvelisib)
Treatment: drugs - Ofatumumab

Experimental: IPI-145 - IPI-145 is administered orally and supplied as 5 mg and 25 mg formulated capsules

Active Comparator: Ofatumumab - Ofatumumab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg/5mL and 1000 mg/50 mL


Treatment: drugs: IPI-145 (duvelisib)


Treatment: drugs: Ofatumumab


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival (PFS)</outcome>
      <timepoint>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate (ORR)</outcome>
      <timepoint>Until disease progression or unacceptable toxicity assessed up to 6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hematologic improvements</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival</outcome>
      <timepoint>Every 6 months for up to 3 years after first dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lymph node response rate - Lymph node response defined as greater than or equal to 50% decrease in the SPD of target lymph nodes</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response (DOR)</outcome>
      <timepoint>Time from the first documentation of response to first documentation of progressive disease or death due to any cause</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment- emergent adverse events (TEAEs) and changes in safety laboratory values</outcome>
      <timepoint>30 days plus 7 days from last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics (PK) - Evaluate the PK of IPI-145 and, if applicable, its metabolite(s)</outcome>
      <timepoint>Cycle 2, Cycle 3, and Cycle 7</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of active CLL or SLL that meets at least one of the IWCLL 2008 criteria for
             requiring treatment (Binet Stage = B and/or Rai Stage = I)

          -  Disease that has progressed during or relapsed after at least one previous CLL/SLL
             therapy

          -  Not appropriate for treatment with a purine-based analogue regimen (per National
             Comprehensive Cancer Network [NCCN] or European Society for Medical Oncology [ESMO]
             guidelines), including relapse = 36 months from a purine-based chemoimmunotherapy
             regimen or relapse = 24 months from a purine-based monotherapy regimen

          -  A cytogenetics or fluorescence in situ hybridization (FISH) analysis of the leukemic
             cells within 24 months of randomization is required to document the presence or
             absence of del(17p). Note: if a sample from within 24 months is not available, it
             should be evaluated as part of the screening laboratory evaluation to inform
             stratification

          -  Measurable disease with a lymph node or tumor mass &gt; 1.5 cm in at least one dimension
             as assessed by computed tomography (CT)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (corresponds to
             Karnofsky Performance Status [KPS] = 60%)

          -  Willingness by subject to be randomized to receive either ofatumumab or duvelisib at
             the dose and schedule defined in the protocol

          -  Must meet the following laboratory parameters:

               1. Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) = 3 x
                  upper limit of normal (ULN)

               2. Total bilirubin = 1.5 x ULN

               3. Serum creatinine = 2.0 x ULN

               4. Hemoglobin = 8.0 g/dL with or without transfusion support

               5. Platelet count = 10,000 µL with or without transfusion support

          -  For women of childbearing potential (WCBP): negative serum ß-human chorionic
             gonadotropin (ßhCG) pregnancy test within 1 week before randomization (WCBP defined as
             a sexually mature woman who has not undergone surgical sterilization or who has not
             been naturally post-menopausal for at least 24 consecutive months [women = 55 years]
             or 12 consecutive months [women &gt; 55 years])

          -  Willingness of male and female subjects who are not surgically sterile or
             postmenopausal to use medically acceptable methods of birth control from the first
             dose of study drug to 30 days after the last dose of duvelisib and for 12 months after
             last dose of ofatumumab. Sexually active men, and women using oral contraceptive
             pills, should also use barrier contraception

          -  Ability to voluntarily sign consent for and adhere to the entire study visit schedule
             and all protocol requirements

          -  Signed and dated institutional review board (IRB)/independent ethics committee
             (IEC)-approved informed consent form (ICF) before any study specific screening
             procedures are performed</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of Richter's transformation or prolymphocytic leukemia

          -  Uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenia purpura
             (ITP) that is uncontrolled or requiring &gt; 20 mg once daily (QD) of prednisone (or
             equivalent) to maintain hemoglobin &gt; 8.0 g/dL or platelets &gt; 10,000 µL without
             transfusion support

          -  Refractory to ofatumumab (progression or relapse &lt;12 months of receiving ofatumumab
             therapy or &lt;24 months of receiving an ofatumumab- containing regimen)

          -  Prior allogeneic transplant (prior autologous stem cell transplant &gt;6 months prior to
             study entry is permitted)

          -  Known central nervous system lymphoma or leukemia; subjects with symptoms of CNS
             disease must have a negative CT scan or negative diagnostic lumbar puncture prior to
             randomization

          -  Use of any of the following medications or procedures within the specified timeframe:

               -  Use of live or live attenuated vaccines within 30 days prior to randomization

               -  Chemotherapy, radiation therapy, or ablative therapy within 3 weeks of
                  randomization

               -  Tyrosine kinase inhibitor within 7 days of randomization

               -  Other investigational therapy (not included above) within 3 weeks of
                  randomization

          -  Previous treatment with a PI3K inhibitor or BTK inhibitor

          -  Ongoing treatment with chronic immunosuppressants (eg, cyclosporine) or systemic
             steroids &gt; 20 mg prednisone (or equivalent) QD

          -  History of tuberculosis treatment within the preceding two years

          -  Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of
             study treatment (defined as requiring IV antimicrobial, antifungal or antiviral
             agents)

             - Subjects on antimicrobial, antifungal or antiviral prophylaxis are not specifically
             excluded if all other inclusion/exclusion criteria are met and there is no evidence of
             active infection at randomization

          -  Human immunodeficiency virus (HIV) infection

          -  Prior, current, or chronic hepatitis B or hepatitis C infection

          -  History of alcohol abuse or chronic liver disease (other than metastatic disease to
             the liver)

          -  Unable to receive prophylactic treatment for pneumocystis or herpes simplex virus
             (HSV)

          -  Baseline QT interval corrected with Fridericia's method (QTcF) &gt; 480 ms (average of
             triplicate readings) Note: This criterion does not apply to subjects with a right or
             left bundle branch block (BBB)

          -  Unstable or severe uncontrolled medical condition (eg, unstable cardiac function,
             unstable pulmonary condition), or any important medical illness or abnormal laboratory
             finding that would, in the investigator's judgment, increase the subject's risk while
             participating in this study

          -  Concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ
             of the cervix, bladder, or prostate not requiring treatment. Subjects with previous
             malignancies are eligible provided that they have been disease free for =2 years

          -  History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia
             requiring medication or mechanical control within the last 6 months

          -  Administration of medications or foods that are strong inhibitors or inducers of CYP3A
             within 2 weeks of randomization

          -  Prior surgery or gastrointestinal dysfunction that may affect drug absorption (eg,
             gastric bypass surgery, gastrectomy)

          -  Major surgery or invasive intervention within 4 weeks prior to randomization

          -  Pregnant or breastfeeding women

          -  Hypersensitivity to ofatumumab or its excipients</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Bedford Park</hospital>
    <hospital> - East Melbourne</hospital>
    <hospital> - Melbourne</hospital>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>3058 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Sint- Niklaas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Argenteuil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bobigny</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Caen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont-Ferrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Roche Sur Yon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Limoges Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vendœuvres</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Köln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rostock</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Gyor</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kaposvár</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pecs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lecce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Meldola</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ravenna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rimini</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Palmerston North</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pamplona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bournemouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Verastem, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A Phase 3 clinical trial to examine the efficacy of IPI-145 monotherapy versus ofatumumab
      monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or
      Small Lymphocytic Lymphoma (SLL).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02004522</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Hagop Youssoufian, MD</name>
      <address>Verastem, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>